Document is current
Any future updates will be listed below
-
Authors
Kanellopoulos, Alexandros
Koster, Linda
de Lavallade, Hugues https://orcid.org/0000-0002-4988-2564
OrtÃ, Guillermo https://orcid.org/0000-0002-7889-5807
Francis, Sebastian
Passweg, Jakob https://orcid.org/0000-0001-7092-3351
Apperley, Jane https://orcid.org/0000-0002-1710-1794
Bethge, Wolfgang https://orcid.org/0000-0001-6052-2618
Rabitsch, Werner
Clay, Jennifer
Forcade, Edouard https://orcid.org/0000-0002-8873-2868
Hurst, Erin
Besley, Caroline
Kinsella, Francesca
Aljurf, Mahmoud https://orcid.org/0000-0003-3942-7370
Huang, He
Ho, Aloysius https://orcid.org/0000-0003-1299-8560
Hilgendorf, Inken https://orcid.org/0000-0003-2038-9730
Choi, Goda
Ayuk, Francis
Grzegorz, Helbig
Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Richardson, Deborah https://orcid.org/0000-0002-8858-923X
Morozova, Elena https://orcid.org/0000-0002-9605-485X
Prejzner, Witold
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Armstrong, Christopher https://orcid.org/0000-0001-5704-7895
Raj, Kavita https://orcid.org/0000-0002-8258-354X
Drozd-Sokolowska, Joanna https://orcid.org/0000-0002-4562-6264
Chalandon, Yves https://orcid.org/0000-0001-9341-8104
McLornan, Donal P. https://orcid.org/0000-0003-1224-091X
- License Information
-
More Information
Article History
Received: 16 November 2025
Revised: 6 March 2026
Accepted: 31 March 2026
First Online: 10 April 2026
Competing interests
: AK: AK has received consulting fees from Jazz and travel support from Jazz and Medac. YC: Y.C. has received consulting fees for advisory board from MSD, Novartis, Incyte, BMS, Pfizer, Abbvie, Roche, Jazz, Gilead, Amgen, Astra-Zeneca, Servier, Takeda, Pierre Fabre, Medac; Travel support from MSD, Roche, Novartis, Pfizer, BMS, Gilead, Amgen, Incyte, Abbvie, Janssen, Astra-Zeneca, Jazz, Pierre Fabre, Sanofi all via the institution. DM: DM has received consulting fees for advisory boards and /or speaker fees from Novartis, Abbvie, GSK and BMS. He has also received research funding from Novartis. GO: GO has received consulting fees for advisory board and / or speaker fees from Chiesi, Jazz, MSD, Novartis, Pfizer, Sanofi and Therakos. He has also received travel support from Incyte, Jazz, Novartis, Pfizer and Sanofi. Research funding from Incyte (institutional). JFA: JFA has received consulting fees for advisory boards and /or speaker fees from Ascentage, Incyte, Novartis, Paladin and Terns. She has also received research funding from Incyte and Pfizer. FK: FK has received consulting fees for advisory board and / or speaker fees from Incyte, Sanofi, Vertex, Therakos, and Jazz. FK has received research funding from Gilead. IH has received speaker fees from Amgen, Abbvie, Novartis, Medac and Takeda. She has also received travel support from Amgen, Jazz, Medac, Neovii and Sanofi. GH: GH has received speaker fees from Abbvie, Novartis, Gilaed, Servier, BMS, Pfizer, GSK. The other authors did not state any competing interests relating to this study.
: All methods were performed in accordance with the relevant guidelines and regulations. This was a descriptive study led by the EBMT CMWP, wherein participating transplant centres provided responses reflecting their institutional clinical practices. Centre answers are based on their patient outcomes, and all patients have provided informed consent according to local regulations to report pseudonymized data to the EBMT. As this study was a descriptive survey of institutional clinical practices directed at transplant centres rather than direct interventional human subjects research, formal institutional ethics committee approval was waived.
